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Abstract
Mannose-binding lectin (MBL) is a key soluble effector of the innate immune system that recognizes pathogen-specific
surface glycans. Surprisingly, low-producing MBL genetic variants that may predispose children and immunocompromised
individuals to infectious diseases are more common than would be expected in human populations. Since certain immune
defense molecules, such as immunoglobulins, can be exploited by invasive pathogens, we hypothesized that MBL might
also enhance infections in some circumstances. Consequently, the low and intermediate MBL levels commonly found in
human populations might be the result of balancing selection. Using model infection systems with pseudotyped and
authentic glycosylated viruses, we demonstrated that MBL indeed enhances infection of Ebola, Hendra, Nipah and West Nile
viruses in low complement conditions. Mechanistic studies with Ebola virus (EBOV) glycoprotein pseudotyped lentiviruses
confirmed that MBL binds to N-linked glycan epitopes on viral surfaces in a specific manner via the MBL carbohydrate
recognition domain, which is necessary for enhanced infection. MBL mediates lipid-raft-dependent macropinocytosis of
EBOV via a pathway that appears to require less actin or early endosomal processing compared with the filovirus canonical
endocytic pathway. Using a validated RNA interference screen, we identified C1QBP (gC1qR) as a candidate surface receptor
that mediates MBL-dependent enhancement of EBOV infection. We also identified dectin-2 (CLEC6A) as a potentially novel
candidate attachment factor for EBOV. Our findings support the concept of an innate immune haplotype that represents
critical interactions between MBL and complement component C4 genes and that may modify susceptibility or resistance to
certain glycosylated pathogens. Therefore, higher levels of native or exogenous MBL could be deleterious in the setting of
relative hypocomplementemia which can occur genetically or because of immunodepletion during active infections. Our
findings confirm our hypothesis that the pressure of infectious diseases may have contributed in part to evolutionary
selection of MBL mutant haplotypes.
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Introduction
Mammalian viruses have co-evolved with the host’s immune
machinery because viruses are obligate intracellular parasites. The
outcome of host-virus interactions rests on a delicate balance
between the host’s defenses and the damage caused by viruses [1].
In addition, viruses have developed counter-adaptation strategies
to escape immune defenses by evading, suppressing or manipu-
lating the host’s immune response. Consequently, favorable
genetic traits in both hosts and viruses have been naturally
selected over time [2].
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Human mannose-binding lectin (MBL), a prototypic soluble
calcium-dependent (C-type) lectin, is a key first line host defense
molecule and immune regulator. MBL collaborates with a network
of host defenses such as complement components and diverse
cellular receptors such as C-type lectin, scavenger, and comple-
ment receptors, integrins, and Toll-like receptors (TLR) to prime
long-lived adaptive immunity [3,4]. MBL recognizes specific
molecular patterns of oligosaccharides including D-mannose, L-
fucose, glucose, and N-acetylglucosamine that decorate the surface
of many viruses such as Ebola virus (EBOV), Hendra and Nipah
viruses, HIV-1, HIV-2, influenza viruses, and severe acute
respiratory syndrome coronavirus [5,6]. MBL oligomers form
complexes with MBL-associated serine protease (MASP) dimers
which activate the lectin complement pathway and enhance
opsonophagocytosis of pathogens [5]. The average human MBL
serum concentration is 1.5 mg/ml (range, 0 to .5 mg/ml) [7] but
up to 30% of the human population has levels,500 ng/ml, which
may be associated with increased susceptibility to infections in
young children and immunocompromised individuals [5]. Inter-
individual variability of MBL concentrations is caused by
structural variant alleles (B, C, and D) in exon 1 of the MBL2
gene which disrupt assembly of MBL high-order oligomers and
lead to reduced MBL concentrations and activity. Single
nucleotide polymorphisms in the promoter region (H/L, X/Y),
59 untranslated region (P/Q) and other regulatory sites also modify
serum concentrations. Together, these sequence variations define
at least 7 common human MBL haplotypes that dictate MBL
concentrations and complement-activating capacity. MBL variant
alleles are present in approximately 20% to 50% of individuals.
Higher rates occur in indigenous people from Africa and South
America [8]. The reason for such high rates of sequence variations
is an unresolved controversy [9,10]. It has been postulated that a
high-producing ancestral haplotype (A allele) evolved into multiple
low MBL-producing haplotypes because of heterotic balanced
selection in which individuals carrying structural and regulatory
heterozygous polymorphisms had a survival advantage [11]. It is
not known whether viral infections exerted such selective pressure
over time.
EBOV is a non-segmented, negative-strand RNA virus of the
order Mononegavirales and family Filoviridae that can cause rapidly
fatal viral hemorrhagic fevers in part by dysregulating the innate
immune system. Its highly glycosylated viral envelope glycoprotein
(GP1,2) mediates receptor binding (GP1) and virus-host cell
membrane fusion (GP2) by targeting ubiquitous lectins and other
molecules expressed by macrophages, dendritic cells and endo-
thelial cells [12,13]. We previously demonstrated that recombinant
human MBL (rhMBL) binds EBOV GP1,2 (referred to as GP)
lentiviral virion-like particles and wild-type-like EBOV in a specific
and dose-dependent manner [6,14]. Treatment of mice infected
with 3,0006LD50 native EBOV using supraphysiological dosages
of rhMBL had a protective effect which required intact
complement component 3 (C3) function [15]. Taken together,
these data suggested that MBL and the lectin complement
pathway can influence the course of EBOV infections.
Viruses infect cells by co-opting existing cellular structures or
functions that are responsible for endocytosis of fluid and small
particles, cell-cell recognition, ion transport, and binding to the
extracellular matrix. First, viruses bind to attachment factors and/
or cognate receptors which help concentrate the virus on the cell
surface. Upon binding, receptors then promote endocytosis or
trigger direct fusion of viral and host cell-membranes [16]. EBOV
is internalized primarily by macropinocytosis [17] whereas certain
other viruses enter cells via clathrin-coated pits, caveolar/lipid-raft
structures, or clathrin2 and caveolin/raft-independent mecha-
nisms [16]. In general, the specificity of receptor binding
determines cell tropism, and the type of receptor engaged by the
virus determines the choice of endocytic pathway. Notably, EBOV
has very broad cell tropism, especially later in the course of
infection, and it may bind to multiple attachment factors, notable
among which are numerous lectins (DC-SIGN/L-SIGN, MGL
[CLEC10A], LSECtin [CLEC4G]) and Niemann-Pick C1 en-
dosomal membrane protein. In addition, Tyro3 family members
(Axl, Dtk, Mer) and b1 integrins which are widely expressed have
been implicated in Ebola-GP mediated cell entry [13,18]. T-cell
immunoglobulin and mucin domain 1 (TIM-1) was recently
proposed as an epithelial receptor that binds the EBOV GP1
receptor binding region [19] but the cognate receptor(s) of
monocytes, macrophages and dendritic cells have yet to be
identified.
A variety of viruses including EBOV, Dengue viruses, West Nile
virus (WNV), HIV-1, Coxsackie B virus and Ross River virus
exploit antibodies or activated complement components to
enhance entry into target cells [20,21,22]. This process, called
antibody-dependent enhancement (ADE), starts with cross-linking
of virus-antibody or virus-antibody-complement complexes to Fcc
(CD32) or complement receptors, respectively [20,21,23]. The
virus may then be coupled to its cognate receptor on the cell
surface, thereby facilitating entry. It is noteworthy that viral
specific antibodies can either neutralize or enhance productive
EBOV and WNV infection depending on the antibody concen-
tration and class, complement component concentration, type of
cells, density of epitopes, and effector mechanisms mediated by the
crystallizable fragment (Fc) of the antibody [22,24,25]. It has also
been postulated that the rapid spread of EBOV to secondary
target cells (e.g. hepatocytes and endothelial cells) occurs by means
of ADE via widely distributed C1q receptors [22].
MBL has been described as an ‘‘ante-antibody’’ which
represents a primitive non-clonal form of humoral immunity and
which evolutionarily predated antibodies [26]. Analogous to
antibodies, MBL mediates opsonophagocytosis and it can bind
to cellular receptors via its collagenous tail [27]. In addition, MBL
has structural and functional homology with C1q which binds
cognate cellular receptors and/or activates the complement
pathway via actions of serine proteases [28]. Given the functional
similarities between MBL and either antibodies or C1q, we
considered that a novel MBL receptor-mediated mechanism for
enhancing infection by EBOV and other viruses whose virions are
highly glycosylated might explain some of the heterotic balanced
selection that may contribute to the evolutionary divergence of
human MBL haplotypes.
Given our proposed model that lectins might enhance EBOV
infection, we investigated the possibility that human MBL could
enhance infection of human cells by EBOV GP-pseudotyped
lentiviruses, wild-type-like EBOV and other glycosylated virions in
low complement conditions. After initial confirmation of our
model, we pursued mechanistic studies of the dynamics of MBL-
mediated endocytosis and identified candidate MBL and viral
receptors using an RNA interference (RNAi) approach.
Materials and Methods
Ethics statement
We obtained written informed consent from eligible healthy
adult volunteers for blood samples according to a protocol
approved by the Massachusetts General Hospital Institutional
Review Board.
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Reagents and antibodies
All reagents were purchased from Sigma-Aldrich (St. Louis,
MO) except as listed. Jasplakinolide was purchased from EMD
Biosciences (San Diego, CA) and Latrunculin B from Enzo Life
Sciences International (Plymouth Meeting, PA). Wild-type-like
cyanovirin-N (P51G mutant) was kindly donated by E. Matei [29].
RhMBL was provided by Enzon Pharmaceuticals (Bridgewater,
NJ)[30]. Notably, rhMBL is similar in structure and function to
native human MBL but forms predominantly high molecular mass
multimers .350 kDa [30]. Complement component C2-depleted
serum was purchased from Quidel (San Diego, CA). Recombinant
human C2 and interleukin-4 (IL-4) were purchased from R&D
Systems (Minneapolis, MN). N-glycosidase F (PNGase F) and
endoglycosidase H were from New England Biolabs (Ipswich,
MA). Anti-hMBL antibody HYB 131-01 (BioPorto, Gentofte,
Denmark) was used for mannan-binding and complement
component C4 cleavage assays. The anti-human MBL neutraliz-
ing monoclonal antibody, 3F8, was produced by G.L. Stahl [31].
The isotypic control IgG1 was obtained from Beckman Coulter
(Hebron, KY). Puromycin and alamarBlue cell viability reagent
(resazurin) were from Invitrogen (Carlsbad, CA). Thermolysin
(Sigma-Aldrich) was derived from Thermoproteolyticus rokko. Biotiny-
lated Hippeastrum hybrid (amaryllis) lectin was obtained from
Vector Laboratories (Burlingame, CA).
Cells and culture
Cell lines were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in a humid-
ified 37uC incubator with 5% CO2 in the following media:
HEK293F and Vero E6 cells, Eagle’s Minimum Essential Medium
(EMEM); HEK293T cells, Dulbecco’s Modified Eagle Medium
(DMEM) with 1% Hepes; HEK 293S N-acetylglucosaminyltrans-
ferase I2 (GnTI2) cells, DMEM:F12, and THP-1 cells and
peripheral blood mononuclear cells (PBMC), RPMI-1640. Media
were supplemented with 10% fetal bovine serum (Invitrogen),
100 U/ml penicillin, and 100 mg/ml streptomycin. Of note,
HEK293F cells adhere to tissue culture microplates (Corning)
when incubated with FBS-supplemented media. PBMC were
isolated from fresh single-donor buffy coat samples from the
Massachusetts General Hospital (MGH) Blood Bank using
Vacutainer CPT Cell Preparation Tubes with sodium citrate
(BD, Franklin Lakes, NJ) according to the manufacturer’s
instructions. 66107 cells were seeded in RPMI-1640 with 10%
FBS in a 10 cm tissue-culture dish at 37uC for 3 hours after which
non-adherent cells were removed by washing twice with RPMI-
1640. Adherent PBMC were detached with a cell scraper and
seeded at 2.56105/well in a 96-well tissue-culture plate in RPMI-
1640 with 10% FBS and 50 ng/ml M-CSF to induce differenti-
ation of monocyte-derived macrophages (day 0). Then cells were
incubated at 37uC, fresh media (50 ml) and M-CSF (50 ng/ml)
were added on day 4, cells were infected on day 7, and assayed for
infection on day 10.
MBL functional assays and MBL2 genotyping
Mannan-binding and C4 cleavage assays were performed as
described elsewhere [6]. We isolated genomic DNA from 3 ml
whole blood obtained from 35 ethnically diverse, consenting
healthy volunteers according to the manufacturer’s instructions
(Gentra Puregene Blood Kit, Qiagen, Valencia, CA). Primers and
PCR reaction conditions for MBL2 genotyping were adapted from
Steffensen et al. [32]. Modifications to the protocol are described
in Methods S1.
Virus preparation
Pseudotyped viruses. HIV-EBOV GP, HIV-EBOV-DGP
NTDL6 (217 amino acids were deleted from the mucin-rich
region downstream of the EBOV binding region), HIV-vesicular
stomatitis virus (VSV)-G, and HIV-envelope (env) negative
(gp1202) virions, which encoded firefly luciferase, were produced
as described elsewhere [6,14,33]. HIV-1 was used for all
pseudotyped viral constructs. Pseudotyped virion-like particle
concentrations were determined by ELISA quantitation of HIV-
1 p24 core protein according to the manufacturer’s instructions
(Alliance HIV-1, PerkinElmer, Waltham, MA).
Wild type or wild-type-like viruses. Wild-type-like recom-
binant EBOV (1976 Mayinga variant)-eGFP (GenBank accession
number NC002549), and Hendra and Nipah viruses were
prepared in BSL4 laboratories, and quantified with a spectroflu-
orometer or immunoassays, respectively as described elsewhere
[6,34,35,36]. Details of the Hendra and Nipah virus variants are
reported elsewhere [35,36]. The WNV replicon plasmid
(pWIIrep-GFP) was kindly provided by Dr. Doms (University of
Pennsylvania School of Medicine). The coding region of WNV
(Strain NY99) capsid (C), premembrane (prM), and envelope (E)
proteins was cloned into the pCAGGS.MCS vector. A glycosyl-
ation mutant of WNV E protein (N154Q) was introduced using
the QuikChange method (Invitrogen). West Nile virion-like
particles were produced as previously reported [37,38] and
described in the Methods S1.
Infection assays
All infections were performed in 96-well white clear bottom cell
culture microplates unless indicated otherwise.
Pseudotyped virions (single-round infection
assays). Adherent HEK293F and HEK293S GnTI2 cells
(56103/100 ml) were incubated with EMEM or DMEM/F12
(2.5% FBS), respectively for 48 hours until 60–70% confluent
(approximately 2.56104/100 ml). THP-1 cells (56104/100 ml),
stimulated with PMA (10 ng/ml) and supplemented with IL-4
(100 ng/ml) to upregulate potential EBOV receptors [39], became
differentiated and adherent after 72 hours of incubation in RPMI
1640 (2.5% FBS). Monocyte-derived macrophages were prepared
and maintained as described above. The inoculum consisted of
1200 pg p24/100 ml for each viral construct unless indicated
otherwise. 1200 pg HIV p24 corresponds approximately to 26107
HIV-EBOZ GP virion-like particles according to the formula: p24
mass 6 (1 mol/MW p24 [24,000 g/mol]) 6 (6.0261023 mole-
cules/1 mol) 6 (1 virion/2000 molecules). Based on these
calculations, the estimated virion-like particle to cell ratio
(approximation to MOI) for HEK293F and HEK293S cells was
800:1, and 400:1 for THP-1 cells. Before infecting cells, the sera,
virion-like particles and/or cells were prepared as follows: 1) MBL-
replete or –deficient (LYPB/LYPB; MBL ,0.6 ng/ml) sera were
preincubated with dilutions of oligosaccharides, mannan, polyeth-
ylene glycol, EDTA, 3F8 or isotypic control IgG1 at 37uC for 30
minutes, 2) virion-like particles were preincubated with dilutions of
human sera (pretreated as above for certain experiments), rhMBL,
cyanovirin-N, PNGase F, endo H, thermolysin or serum-free
media at 37uC for 1 hour, or 3) cells were preincubated with
dilutions of pharmacologic inhibitors of endocytosis at 37uC for
1 hour, or N-glycosylation inhibitors at 37uC for 18 hours, and
appropriate controls (dimethyl sulfoxide [DMSO] or methanol for
endocytosis inhibitors). Reagents were diluted in DMEM or
Veronal-buffered saline (VBS, barbital 2.5 mM, sodium barbital
1.5 mM, NaCl 0.14 M) to achieve optimal rates of infection. The
final CaCl2 concentration was 5 mM unless indicated otherwise.
Media were removed from the cells (except for the media
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containing pharmacologic inhibitors of endocytosis), and the
inoculum preparation was added. Of note, cells preincubated
with methyl-b-cyclodextrin were washed twice with phosphate-
buffered saline (PBS) before virus was added to obviate disruption
of virion glycans or envelopes. Microplates were centrifuged at
10006g for 2 hours at room temperature (spinoculation step), and
then incubated at 37uC in 5% CO2 for 3 hours. Thereafter, the
inoculum preparation was replaced with fresh media containing
10% FBS and incubated at 37uC in 5% CO2 for 40 hours.
Cell viability was assessed with 10% alamarBlue reagent
(resazurin reduction assay) by measuring fluorescence after 1 hour
at 37uC (570 nm excitation, 585 nm emission) in certain
experiments when the use of various virion-like particles (e.g.
HIV-EBOV, HIV-VSV-G, HIV-env negative and HIV-EBOV
DGP NTDL6) or potentially toxic chemicals (e.g. EDTA, N-
glycosylation inhibitors) may have differentially impaired cell
proliferation. Cells were lysed and single round infection of cells
was quantified by detection of chemiluminescence measured with
a luciferase assay according to the manufacturer’s instructions
(Promega, Madison, WI) [6]. Fluorescence and luminescence were
read with a Spectramax M5 microplate reader (Molecular
Devices, Sunnyvale, CA). Luciferase values were expressed as
relative light units per second (RLU/sec) and adjusted for cell
viability where appropriate: Adjusted luciferase value is
defined as luciferase RLU/sec 4 alamarBlue fluorescence units.
Experiments were performed twice in quadruplicate.
Wild type-like recombinant EBOV (Mayinga variant)-
eGFP virus. We modified a previously described infection assay
[6,34]. Briefly, virions were preincubated with media or 5% MBL-
deficient serum (MBL,0.6 ng/ml) with or without 10 mg/ml
MBL (final concentration) at 37uC for 1 hour and then the virion
preparation was added to 46104/100 ml HEK293T cells at a
multiplicity of infection of 0.1 at 37uC for 1 hour. In certain
experiments, MBL was preincubated with mannan or cells were
preincubated with tunicamycin as described above. Thereafter,
the viral inoculum was replaced with fresh DMEM and incubated
at 37uC for 72 hours. Fluorescence was read with a spectrofluo-
rometer (Molecular Devices; excitation, 485 nm; emission,
515 nm). Experiments were performed twice in triplicate.
Hendra virus and Nipah virus. The infection assay was
described in detail elsewhere [6] with the following modification.
Viruses (10,000 TCID50/ml) were preincubated with 10% heat-
inactivated MBL-deficient serum (MBL,0.6 ng/ml) with or
without 10 mg/ml rhMBL at 37uC for 45 minutes before adding
the inoculum to Vero E6 cells at 37uC for 1 hour. Experiments
were performed twice in duplicate.
West Nile virus. 16104 HEK293T cells/well were plated in
a 24-well tissue-culture plate in 1 ml DMEM with 10% FBS at
37uC for 24 hours. 250 ml West Nile virion-like particles were
preincubated with 50 ml DMEM, 2% MBL-deficient human
serum, with or without 10 mg/ml rhMBL at 37uC for 1 hour. Cell
culture medium was replaced with 300 ml of West Nile virion-like
particle preparation and the plate was spinoculated at 2,0006g for
1 hour. The virion-like particle preparation was replaced with
1 ml/well DMEM and 10% FBS, and incubated at 37uC for
24 hours. Cells were detached using TrypLE (Invitrogen) and
washed three times with PBS at 4uC. Cells were resuspended in
300 ml PBS and rates of transduction were assayed by flow
cytometry. Experiments were performed twice in triplicate.
Flow cytometry
Various concentrations of FITC-dextran were preincubated
with dilutions of rhMBL in RPMI-1640 with 10% FBS at 37uC for
30 minutes. FITC-dextran with or without MBL was then
incubated with PMA-stimulated, IL-4 supplemented THP-1 cells
(16105/100 ml reaction volume) in the dark at 37uC for 1 hour.
The effect of MBL on FITC-dextran endocytosis and GFP
expression in West Nile virion-like particle-transduced HEK293T
cells were analyzed with flow cytometry. Data were acquired using
a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA)
and analyzed using CellQuest Pro software (BD Biosciences).
Percentage and mean fluorescent intensity (MFI) of GFP-
expressing cells within the live cell population were determined
and analyzed as a function of their product (percentage6MFI).
Experiments were performed twice in triplicate.
RNA interference screen
pLK0.1 infection. We performed an RNAi loss-of-function
screen with high-titer pLKO.1 lentiviral vectors, which carry the
puromycin-resistance gene and drive short hairpin RNA (shRNA)
expression from a human U6 promoter, to identify potential
receptors or attachment factors for EBOV and/or MBL-mediated
viral uptake. We obtained 4 to 5 unique shRNA constructs per
gene from The RNAi Consortium (Broad Institute, Massachusetts
Institute of Technology, MA)[40] targeting 24 candidate lectin,
scavenger and other human receptors or receptor-like molecules
(Table S1) and cathepsin-L (CTSL1), some of which have been
implicated in EBOV pathogenesis (e.g. TYRO3, DC-SIGN,
MGL, LSECtin, CTSL1) [41,42,43,44,45,46,47], as well as an
empty pLK0.1-puromycin vector. After cultivating HEK293F cells
(1.256104/100 ml) in 96-well microplates in EMEM with 10%
FBS at 37uC in 5% CO2 for 24 hours (,60% confluence),
adherent cells were transduced in quadruplicate by incubating
shRNA viruses and control vectors (4.66108 particles) with
hexadimethrine bromide (6 mg/ml) and cells at 37uC for 18 hours.
The medium was replaced with fresh complete medium contain-
ing 5 mg/ml puromycin (optimal concentration was determined by
a preliminary kill curve experiment) and incubated for 48 hours at
which time cell viability was assayed with alamarBlue reagent
according to the manufacturer’s instructions.
HIV-EBOV-GP infection (single round). We preincubated
pseudotyped EBOV virion-like particles (1000 pg p24/100 ml)
with or without MBL (10 mg/ml) in VBS at 37uC for 1 hour, and
then used the virion-like particles to infect quadruplicate shRNA-
infected HEK293F cells maintained in 5 mg/ml puromycin. After
48 hours, we measured luciferase expression as described in
Infection assays and adjusted the results for cell viability. We
calculated percentage change in luciferase activity caused by
shRNAs relative to the empty pLK0.1 control vector. A positive
hit was defined as $66% reduction in infection by at least two
shRNA constructs for any particular gene.
Confirmation of knockdown by western blot
We cultivated HEK293F cells (6.66104/well) with DMEM and
10% FBS in 6-well format for 24 hours. We then transduced cells
with 1.56108 shRNA viruses identified as hits in the RNAi screen
as well as non-targeting shRNA-GFP controls with 6 mg/ml
hexadimethrine bromide. After 24 hours at 37uC, we replaced the
inoculum preparation with fresh complete media containing 5 mg/
ml puromycin and we harvested cells after at least 72 hours.
Cellular lysates were extracted from shRNA-treated cells with the
Qiagen AllPrep protein kit and protein concentrations were
measured using a Nanodrop spectrophotometer. 10 mg lysates
were mixed with Laemmli loading buffer and DTT (50 mM final
concentration), fractionated on 4–20% gradient minigels (Biorad)
and transferred to nitrocellulose membranes. Protein molecular
weights were determined using the Invitrogen NOVEX pre-
stained protein standard. Membranes were blocked with 2.5%
Lectin-Dependent Enhancement of Ebola Viruses
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Figure 1. MBL enhances HIV-EBOV GP infection of HEK293F cells in low complement conditions.We used luciferase-encoding HIV-EBOV-
GP virion-like particles to infect 56103 adherent HEK293F cells. Viruses (350 pg p24/100 ml) were preincubated with physiological concentrations of
rhMBL (0.1–10 mg/ml) in (A) DMEM or (B) MBL-deficient (,0.6 ng/ml) 5% human serum for 1 hour at 37uC. We analyzed infection rates after 40 hours.
Luciferase absorbance values were adjusted for cell viability by normalizing to alamarBlue fluorescence units (resazurin reduction assay) and results
are expressed as Adjusted Luciferase Values. Significant differences are shown. * and ** p,0.05 (HIV-VSV-G vs both other virions at 0 and 0.1 mg/ml
supplemental rhMBL, respectively), { and { p,0.05 (HIV- envelope negative vs both other virions at 1 and 10 mg/ml supplemental rhMBL,
respectively). Also shown in (B) is the reduced capacity of rhMBL to enhance infection by HIV-EBOV-DGP NTDL6 (mutated GP lacks 217 amino acids in
the heavily glycosylated mucin-rich region) compared with that for HIV-EBOV GP, which contains intact mucin-rich regions (1.3- vs 17.22fold
enhancement, respectively, p,0.001). Experiments were performed twice in quadruplicate. (C) We preincubated HIV-EBOV GP with serial dilutions of
serum from three individuals with undetectable (,0.6 ng/ml; LYPB/LYPB), intermediate (2,181 ng/ml; LYPA/HYPD) or high (5,424 ng/ml; HYPA/LYQA)
MBL concentrations. Shown are luciferase values. * p,0.05 (high level MBL vs low or intermediate level MBL at 1% serum dilution), **, { and { p,0.05
(all pairwise comparisons at 2%, 5% and 10% serum dilutions, respectively), # p,0.05 (all pairwise comparisons at 30% serum dilution). Experiments
Lectin-Dependent Enhancement of Ebola Viruses
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BSA dissolved in PBS-T solution (120 mM NaCl, 2.7 mM KCl,
10 mM phosphate buffer, pH 7.4, 0.1% Tween-20) for 1 hour,
followed by incubation with primary antibodies at 4uC overnight.
Dilutions of selected antibodies were as following: C1QBP (Santa
Cruz) 1:1000, CLEC6A (Abcam) 1:1000, CLEC7A (Biovision)
1:5000, CLEC10A (Novus Biologicals) 1:500, and actin (Millipore)
1:5000. Membranes were then triple-washed in PBS-T for 5
minutes, and incubated with appropriate secondary antibodies:
goat anti-rabbit IgG-HRP or goat anti-mouse IgG-HRP (both
Santa Cruz) at 1:5000 in PBS-T for 30 minutes. After of triple
washing, ECL reagents were applied to the membranes and
visualized by autoradiography.
mRNA expression of candidate genes was measured by
quantitative real-time PCR as described in detail (see Methods
S1 and Table S2).
Statistics
Normally distributed data were compared with analysis of
variance tests, skewed data were analyzed with Mann-Whitney U
or Kruskal-Wallis tests, and categorical data were compared with
Student’s t- or Fisher exact tests, where appropriate. The Tukey
test was used for all-pairwise multiple comparison procedures.
Data in figures are shown as mean 6 standard error of the mean.
All tests were two-tailed. p values ,0.05 were considered
statistically significant.
Results
Complement contributes to differential antiviral effects
of human MBL
Mannose-binding lectin is a key host defense molecule that
collaborates with complement and other soluble and cell-derived
molecules to limit invasion by pathogens [4,5]. We previously
demonstrated that rhMBL effectively inhibited infection of human
cells by EBOV GP-pseudotyped lentiviral virions and wild type-
like EBOV in the presence of active complement in serum [6,15].
In the course of those experiments, we were not surprised to
confirm that complement was essential for the inhibitory effects of
rhMBL. In its absence, we found preliminary evidence suggesting
a paradoxical rhMBL-dependent increase in EBOV infection in a
variety of human cell lines including 293F cells, which produced
highly reproducible results and which potentially bind the EBOV
receptor binding region to a greater extent than 293 T cells [48].
Given the wealth of examples where viruses subvert immune
defense molecules during virus entry and given the evidence for
selective pressure against high-producing MBL haplotypes in
human populations, we sought to define the mechanisms by which
MBL might enhance infection of human cells by EBOV. We also
evaluated the effects of MBL on infection by other glycosylated
viruses in low complement states to determine whether this
mechanism was relevant for glycosylated viruses in general.
Recombinant and native human MBL enhance EBOV
infection in low complement states
We first found that HIV-EBOV GP virion-like particles infected
HEK293F cells to a greater extent in the presence of MBL than in
its absence. RhMBL enhanced infection in a dose-dependent
manner either in the absence of serum (Figure 1A) or with a
relatively low concentration (5%) of MBL-deficient serum
(Figure 1B). In each of these experiments, MBL maximally
enhanced viral infection by approximately 18-fold. RhMBL-
dependent enhancement of HIV-EBOV GP infection required
EBOV glycoprotein since rhMBL did not enhance infection by
HIV-env negative (gp1202) or HIV-VSV-G (Figure 1A, 1B). The
permissive effect of rhMBL was calcium-dependent as expected for
C-type lectins (Figure S1).
To determine whether native hMBL could also enhance EBOV
infections, we collected a panel of human sera with MBL
concentrations and C4 cleavage activity that spanned the normal
range of MBL variation in human populations (Figure S2). We
then tested the relative effects of sera from three individuals with
undetectable, intermediate or high MBL levels on the degree of
HIV-EBOV GP infection of HEK293F cells. The degree of
infection was strongly associated with native MBL levels at serum
concentrations #10% (Figure 1C). Importantly, EBOV infection
was inhibited at serum concentrations .10% in the presence of
higher MBL concentrations (Figure 1C) as we reported previously
[6]. We validated this association by demonstrating strong
correlations between infection and MBL levels using 5% serum
from our panel of human sera (MBL concentration curve,
r2 = 0.85; MBL C4 cleavage activity curve, r2 = 0.83; Figure 1D).
These findings substantiated our hypothesis that native MBL plays
a significant role in enhancing EBOV infection.
Given that MBL and activation of the lectin complement
pathway are required to block EBOV infection [6,14,15], we
questioned what effect inactivation of complement would have on
MBL’s capacity to enhance viral infection. MBL forms a complex
with MBL-associated serine proteases (MASPs) and upon binding
to pathogens, MBL-MASPs sequentially cleave complement
components C4 and C2. The catalytic products of these
complement components form the C4b2a complex which acts as
the C3 convertase, a key enzyme in the lectin complement
pathway. Cleavage and processing of C3 by the C3 convertase
produces several C3-derived components (e.g. iC3b) that are
potent activators of the immune system. iC3b binds complement
receptor 3 (CR3) leading to enhanced phagocytosis by professional
phagocytes and increased cytotoxicity by NK cells. Based on the
fact that complement is heat labile, we showed that heat
inactivation of serum reversed its inhibitory effect on viral
infection at higher serum concentrations, which contained higher
native MBL levels, albeit to varying extents (Figure 1E). To further
define the critical contribution of complement, we compared the
effects of human sera from which C2 was removed by immune
precipitation and that contained or lacked native MBL (Figure 1F).
Notably, C2-depleted MBL-replete serum enhanced infection
maximally at a 50% dilution at which MBL’s concentration was
greatest, an effect that could be reversed by supplementation with
were performed twice in quadruplicate. (D) We preincubated HIV-EBOV-GP virion-like particles with 5% serum from 35 ethnically diverse individuals.
Shown are associations between level of infection and native MBL activity (mannan-binding or C4 cleavage) for each individual (r2 = 0.83, serum C4
cleavage activity; r2 = 0.85, serum MBL-mannan binding). Experiments were performed in quadruplicate. (E) We preincubated HIV-EBOV-GP virion-like
particles with 5% heat-inactivated serum (56uC for 30 minutes) from three individuals with varying MBL levels before infection of cells. (F) We
preincubated HIV-EBOV GP virion-like particles with media or sera (diluted to 1–50%) that were complement component 2 (C2)-replete or depleted,
and that lacked or contained approximately equivalent MBL concentrations (535–650 ng/ml). In addition, C2 depleted serum was reconstituted with
recombinant human C2 (6.5 mg/ml) for comparison. Experiments were performed twice in quadruplicate.
doi:10.1371/journal.pone.0060838.g001
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recombinant human C2. Complement-replete serum with or
without native MBL did not augment infection (Figure 1F).
MBL-mediated viral infection requires specific
glycosylation events known to be essential for its binding
interactions
Mannose-binding lectin recognizes specific configurations of
hexose sugars that include D-mannose, glucose, L-fucose, and N-
acetylglucosamine but not galactose and sialic acid [6]. To
ascertain whether MBL mediates viral infections via the lectin’s
carbohydrate recognition domain, we preincubated 5% human
serum (MBL concentration, 3,621 ng/ml) with competitor carbo-
hydrates. D-mannose, N-acetylglucosamine (Figure 2A) and
mannan, a polymer of mannose (Figure 2B) reduced HIV-EBOV
GP infection, whereas the inhibitory effects of D-galactose, N-
acetylgalactosamine (Figure 2A) and polydisperse polyethylene
glycol (Figure 2B) were significantly less or absent. EDTA also
reduced infection which is consistent with the MBL carbohydrate
recognition domains’ dependence on calcium for binding
(Figure 2A). In a related experiment, 3F8, an anti-MBL
neutralizing monoclonal antibody [31] inhibited HIV-EBOV GP
infection (Figure 2C).
To investigate potential viral epitopes targeted by MBL, we
used cyanovirin-N (CV-N), a cyanobacterial lectin that binds with
high specificity and affinity to Mana1-2Man epitopes at the
terminal ends of N-linked high-mannose oligosaccharides [49].
CV-N inhibited rhMBL-mediated enhancement of HIV-EBOV
GP infection in a dose-dependent manner (IC50 = 197 nM)
indicating that these lectins either shared a viral epitope or
competed via steric hindrance (Figure 2D).
To further explore whether N-linked glycans of the viral GP
were required for MBL-mediated uptake, we deglycosylated HIV-
EBOV GP virion-like particles before adding rhMBL. We
compared the effects of two endoglycosidases, PNGase F and
endo H which predictably cleave N-linked glycans at different sites.
Unlike PNGase F, endo H leaves a single GlcNAc residue which is
a potential binding site for MBL (Figure 3A, B). First, we
confirmed that the endoglycosidases did in fact remove high-
mannose moieties from GP of endoglycosidase-treated HIV-
EBOV viruses. We proved this with a western blot using
biotinylated Hippeastrum hybrid (amaryllis) lectin to detect a-
mannose residues (the hybrid lectin does not bind to a-glucosyl
structures); high-mannose was present in substantial quantities
only in untreated, non-deglycosylated virus (Figure S3). We found
that PNGase F inhibited infection in a dose-dependent manner in
the presence of rhMBL (Figure 3C), whereas heat-inactivated
PNGase F did not inhibit infection (Figure 3D). In contrast to this
effect, neither active nor heat-inactivated endo H inhibited
infection (Figure 3C, D).
We then tested MBL’s effect on HIV-EBOV-DGP NTDL6
which lacks a portion of the glycosylated mucin-rich region [33]
thought to be important for viral pathogenesis [50]. MBL
exhibited reduced capacity to enhance infection by HIV-EBOV-
DGP NTDL6 compared with HIV- EBOV expressing wild type
GP (Figure 1B). To confirm these findings, we preincubated HIV-
EBOV GP virion-like particles with thermolysin, a bacterial
metalloprotease, which cleaves the mucin region and glycan cap of
EBOV GPs [46,48,51]. In support of our hypothesis that MBL
binds the glycan-rich regions, we demonstrated that thermolysin
abrogated the MBL-mediated enhancement of HIV-EBOV GP
infection in a thermolysin-concentration dependent manner. In
the presence of rhMBL, the maximal reduction of viral infection
was 17-fold, whereas there was no inhibition of infection in the
absence of MBL (Figure S4).
Finally, we investigated whether glycoproteins with N-linked
glycans on the cell surface were required for MBL-mediated
uptake. We demonstrated that MBL-mediated infection was
almost completely abrogated by tunicamycin, a chemical inhibitor
of N-acetylglucosaminyltransferase I (GnTI) which initiates the
glycosylation process of cellular glycoproteins (Figure 3E). Prein-
cubation of cells with 1-deoxynojirimicin and swainsonine, which
block carbohydrate trimming by inhibiting glucosidase I-II and a-
mannosidase II [52] also reduced MBL-mediated infection albeit
to a lesser extent than tunicamycin, relative to the control in which
MBL enhanced viral uptake by 18-fold (Figure 3E). These
chemical inhibitors are potentially cytotoxic but we accounted
for differences in cell viability by means of cell proliferation assays
(alamarBlue resazurin reduction assays). Similarly, MBL-mediated
enhanced infection was not seen in HEK293S cells that are
genetically deficient in N-acetylglucosaminyltransferase I
(Figure 3F).
MBL mediates EBOV infection via the canonical
macropinocytosis-like pathway but distinct endocytic
trafficking may define this novel uptake mechanism
Canonical EBOV viral entry utilizes a cholesterol-rich lipid raft-
dependent macropinocytosis-like pathway [17,53]. We tested
several pharmacological perturbants of endocytosis to investigate
whether MBL enhanced viral uptake via this canonical pathway or
if it mediated alternative trafficking. The amiloride analog, EIPA
which is important for macropinosome formation [54], inhibited
infection of HEK293F cells both in the presence or absence of
rhMBL indicating that macropinocytosis is the primary mecha-
nism of entry (Figure 4A). Amiloride hydrochloride, which also
inhibits macropinocytosis, produced similar results (Figure S5).
The absence of a differential effect of methyl-b-cyclodextrin
likewise suggested that lipid rafts were required for viral infection
regardless of the presence of MBL (Figure 4B). Finally, viral
infection was dependent on microtubule function with or without
MBL but importantly, MBL reduced the dependence on
functional actin (Figure 4C–F).
We confirmed that early endosomal acidification is important
for EBOV infection as evidenced by the fact that the lysosomo-
tropic agent bafilomycin A1, a specific and potent inhibitor of
vacuolar H+ ATPase in early endosomes [55], reduced infection
but to a significantly lesser extent in the presence of MBL
suggesting that MBL-mediated endocytosis bypasses early endo-
somes (Figure S5). On the other hand, monensin, a carboxylic
ionophore which inhibits both endosomal acidification and
receptor recycling, attenuated infection to a similar extent in the
presence or absence of MBL (Figure S5).
In agreement with Saeed et al. [17], who used replication-
competent infectious EBOV, we found that dynasore, a potent and
specific dynamin inhibitor, did not have any significant effect on
infection regardless of the presence of MBL (Figure S5). This
suggested that vesicle budding which is common to clathrin- and
caveolin-mediated endocytosis did not contribute to viral entry in
HEK293F cells.
Finally, we tested whether MBL’s role in mediating endocytosis
was target specific. We found that physiological concentrations of
MBL bound effectively to dextran, a prototypic fluid phase marker
of macropinocytosis (Figure 4G). However, MBL did not enhance
the uptake of dextran (Figure 4H). Therefore, we concluded that
MBL enhances EBOV infection in a target-specific manner.
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MBL enhances HIV-EBOV GP infection of cell line-derived
and primary human macrophages
To determine whether MBL can enhance viral uptake of EBOV
in prototypic target cells (monocytes and macrophages) [12], we
tested whether MBL enhanced HIV-EBOV GP infection of
activated THP-1 cells (human monocytic cell line) and primary
human macrophages. We found that rhMBL enhanced infection
of both cell types in low complement conditions (Figure 5A, D). In
a separate experiment, infection of THP-1 cells was significantly
inhibited by preincubating 5% serum (native MBL concentration,
3,621 ng/ml) with competitors: EDTA (98% reduction with
10 mM; Figure 5B), mannan (97% reduction with 10 mg/ml;
Figure 5B) and 3F8 (25% reduction with 0.1 mg/ml; Figure 5C).
Furthermore, MBL’s capacity to enhance infection was signifi-
cantly reduced when the EBOV GP mucin-rich region was
mutated (Figure 5D).
EBOV interacts with novel transmembrane lectin
receptors
We sought to identify candidate receptors that might be
involved in MBL-enhanced EBOV infection. We used short
hairpin (sh)RNA-expressing lentiviral constructs to knock down
expression of 24 candidate lectin, scavenger and other human
cellular receptors (Table S1) in HEK293F cells. We then infected
cells with HIV-EBOV GP in quadruplicate in the presence or
absence of rhMBL. In the first instance, five different shRNAs
targeting the endosomal protease, CTSL1 (Figure S6) reduced
infections by 22–99% in the presence or absence of MBL, which
lent credence to the validity of our assay because proteolysis of
Figure 2. MBL interacts with HIV-EBOV GP via MBL carbohydrate recognition domains. We preincubated 5% serum containing native
human MBL (3,621 ng/ml) with (A) 0, 1 and 10 mM of hexose monosaccharides or EDTA diluted in media, or (B) 0–100 mg/ml of mannan or
polydisperse polyethylene glycol (PEG)(D) at room temperature for 30 minutes. Then we incubated the serum with HIV-EBOV GP (1200 pg p24/
100 ml) at 37uC for 1 hour before infecting adherent HEK293F cells. Luciferase values were adjusted for cell viability using alamarBlue (resazurin
reduction assay). We observed relatively more toxicity associated with 10 mM EDTA but this did not invalidate our results because of our adjustment
for cell viability. (C) We repeated the previous experiments with 3F8, an anti-human MBL monoclonal antibody or an IgG1 isotype control
(preincubation at 37uC for 30 minutes). Significant differences are shown. (D) We preincubated HIV-EBOV GP virion-like particles with cyanovirin (0–
600 nM) at 37uC for 1 hour before incubating the particles with 5% serum in the presence or absence of rhMBL. Luciferase values were adjusted for
cell viability. Experiments were performed twice in quadruplicate.
doi:10.1371/journal.pone.0060838.g002
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Figure 3. MBL targets N-linked glycans on viral and cellular surfaces. The cleavage sites of two endoglycosidases are shown (A,B). N-
glycosidase F (PNGase F) is an amidase that cleaves the linkages between the innermost GlcNAc and asparagine residues within high-mannose,
hybrid and complex oligosaccharides of N-linked glycoproteins, thereby producing carbohydrate-free peptides without any potential ligands for MBL.
Endoglycosidase H (endo H) cleaves linkages within the diacetylchitobiose stem of high-mannose of N-linked glycoproteins, thereby generating a
truncated sugar molecule with one N-acetylglucosamine residue (a potential target for MBL) remaining on the asparagine. Man, mannose; GlcNAc, N-
acetylglucosamine; asn, asparagine; 6 and y, various oligosaccharides; n = 2–150 residues. We preincubated HIV-EBOV-GP virion-like particles
(1200 pg p24/100 ml) at 37uC for 1 hour with (C) PNGase F or endo H (0–10,000 U/ml), or (D) the same concentrations of heat inactivated enzymes.
Then we incubated the viruses with 5% MBL-deficient serum in the presence or absence of rhMBL at 37uC for 1 hour before infecting HEK293F cells.
Significant differences are shown. (E) We preincubated HEK293F cells at 37uC for 1 hour with chemicals (tunicamycin, swainsonine or
deoxynojirimycin) that inhibit various stages of N-linked glycosylation. Then we infected cells with HIV-EBOV-GP virion-like particles (1200 pg p24/
100 ml) that had been preincubated with 5% MBL-deficient serum and supplemented with various concentrations of rhMBL. Significant differences
are shown. * and **, p,0.001 (all pairwise comparisons at 1 and 10 mg/ml rhMBL, respectively). (F) We cultivated HEK293F and HEK293S (deficient in
N-acetylglucosaminyltransferase I) cells in 5% MBL-deficient serum which was supplemented with various concentrations of rhMBL. We infected cells
with HIV-EBOV-GP virion-like particles (1200 pg p24/100 ml) in the absence or presence of 1 mg/ml tunicamycin. Statistical differences among
inhibitors at various rhMBL concentrations are shown. *, ** and {, p,0.005 (all pairwise comparisons at 0.1, 1 and 10 mg/ml rhMBL, respectively).
Luciferase values were adjusted for cell viability using alamarBlue (resazurin reduction assay). All experiments were performed twice in quadruplicate.
doi:10.1371/journal.pone.0060838.g003
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EBOV GP by cathepsin-L in the host cell endosome is a critical
step for viral entry [45,51]. The RNAi Consortium at the Broad
Institute previously validated the specificity of all five cathepsin-L
shRNAs with gene transcription assays (S. Silver, personal
communication). We did not perform a western blot to validate
reduced protein expression. We then proceeded to demonstrate
that knockdown of MGL (CLEC10A) reduced infections by 47–
88% (Figure S6). We verified knockdown of MGL gene expression
by measuring mRNA transcripts relative to non-targeting shRNA
controls and demonstrated variable reductions of 15%,.95% and
55% for MGL shRNA constructs 2, 3 and 4, respectively (Figure
S6; Methods S1). However, in our hands, there were no significant
differences in protein expression compared with an empty pLK0.1
control vector (data not shown). We also found a 70% reduction in
Figure 4. MBL mediates HIV-EBOV GP infection via the canonical macropinocytosis pathway for EBOV but with less dependence on
actin. We preincubated HEK293F cells with (A) EIPA (5-(N-Ethyl-N-isopropyl)amiloride, a potent and specific inhibitor of Na+/H+ exchanger activity),
(B) methyl-b-cyclodextrin (extracts or sequesters cholesterol from the plasma membrane), (C) latrunculin B (blocks actin polymerization), (D)
cytochalasin D (inhibits actin microfilament function), (E) nocodazole (disrupts microtubules), or (F) jasplakinolide (disrupts microtubules) in 5% MBL-
deficient serum in the absence or presence of rhMBL at 37uC for 1 hour. We then infected cells with HIV-EBOV-GP virion-like particles (1200 pg p24/
100 ml). Percentages of infected cells are relative to DMSO controls. Luciferase values were adjusted for cell viability. Experiments were performed
twice in quadruplicate. Significant differences are shown. (G) Absorbance values of an ELISA assay are shown indicating the difference in amount of
rhMBL within the physiological range that binds to immobilized mannan or FITC-dextran (1 mg/100 ml). (H) We preincubated FITC-dextran with
various concentrations of rhMBL at 37uC for 30 minutes and then added the products to PMA-stimulated (10 ng/ml), IL-4-supplemented (100 ng/ml)
THP-1 cells at 37uC for 1 hour. We measured FITC-dextran uptake by flow cytometry and reported the results as mean fluorescence intensity
(geometric mean fluorescence6percentage of cells). Experiments were performed twice in triplicate.
doi:10.1371/journal.pone.0060838.g004
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infection of cells treated with one TYRO3 shRNA which reduced
gene expression by 62% but did not reduce protein expression
(data not shown). These findings are not conclusive but do not
conflict with the roles that these proteins have been reported by
others to play in EBOV pathogenesis [43,47].
We then screened the selected candidate attachment factors
(Table S1). We demonstrated that shRNA-mediated knockdown
of dectin-2 (CLEC6A, dendritic cell-associated C-type lectin 2)
reduced HIV-EBOV GP infection regardless of the presence of
MBL (Figure 6A) and knockdown of C1QBP (gC1qR) reduced
HIV-EBOV GP infection to a significantly greater extent in the
presence of rhMBL than in its absence for one of the shRNA
constructs (Figure 6C; shRNA construct 2, p,0.005), thereby
potentially identifying a novel MBL-mediated viral uptake
pathway. Knockdown of protein expression was confirmed by
western blots in which single clear bands were detected for
CLEC6A (Figure 6B) and for C1QBP (Figure 6D). After adjusting
for variations in protein loading relative to actin controls, we
confirmed that protein expression of CLEC6A was reduced by
40% to 65% by each of four shRNAs (Figure 6B) and that of
C1QBP was reduced by 48% to 68% by each of three shRNAs
(Figure 6D) compared with that of the empty pLK0.1 control
vector. These experiments validated the findings from the
infection assays. We also showed by means of quantitative real-
time PCR that CLEC6A gene transcription was knocked down by
.95% by each of the same four shRNAs.
Figure 5. MBL enhances HIV-EBOV GP infection of THP-1 cells and human monocyte-derived macrophages. (A) We stimulated 56104
THP-1 cells with PMA (10 ng/ml) and supplemented the cells with IL-4 (100 ng/ml) for 72 hours. We preincubated HIV-EBOV GP or HIV-env negative
virion-like particles (1200 pg p24/100 ml) with or without rhMBL before infecting differentiated adherent THP-1 cells cultivated in 5% MBL-deficient
serum. (B) We cultivated 2.56105 PBMC derived from human single-donor buffy coat samples in RPMI-1640 with 10% FBS and stimulated the cells
with M-CSF (50 ng/ml) to induce differentiation of monocyte-derived macrophages. We infected cells with HIV-EBOV GP (WT), HIV-EBOV-DGP NTDL6
(NTDL6, mutated GP lacks 217 amino acids in the heavily glycosylated mucin-rich region) or HIV-env negative (env neg) in the presence or absence of
rhMBL. The box plot represents outliers (dots), 10th and 90th percentiles (whiskers), 25th and 75th percentiles (box) and median values (line).
Significant differences in infection rates are shown. Luciferase values were adjusted for cell viability using alamarBlue (resazurin reduction assay) for
all the above experiments, which were performed twice in quadruplicate.
doi:10.1371/journal.pone.0060838.g005
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MBL enhances wild type-like EBOV and other
glycosylated viral infections
Finally, we confirmed that the MBL-enhancement of viral
infection was relevant for native viral infections by testing wild
type-like EBOV [34]. RhMBL enhanced EBOV infection in low
complement conditions by 75 to 150% (Figure 7A). As seen for
pseudotyped viruses, MBL-dependent enhanced infection was
blocked by preincubating rhMBL with mannan (Figure S7) or
pretreatment of cells with tunicamycin in a dose-dependent
manner (Figure S7). To evaluate the generalizeability of our
observations for other glycosylated viruses, we tested three
additional native viral infection models. RhMBL enhanced native
Nipah and Hendra viral infections in hypocomplementemic
conditions by 20 to 35%, respectively (Figure 7B). In addition,
rhMBL significantly enhanced West Nile virion-like particle
transduction by 150 to 300% in low complement conditions but
it had no effect on a glycosylation-deficient WNV N154Q mutant
strain (Figure 7C).
Discussion
Mannose-binding lectin is a multifunctional pattern recognition
receptor that plays a key role in fine-tuning the innate immune
system [4]. Since MBL deficiency was first discovered as a cause of
a common opsonic defect in children [56], a better understanding
of its diverse functions has evolved [5]. MBL binds to invariant
glycans on diverse microorganisms including EBOV [6,14],
upregulates opsonophagocytosis, activates the lectin complement
pathway, amplifies host responses in cooperation with TLR2/6,
and differentially regulates cytokine production [4,57,58]. Yet, a
cogent explanation for the evolutionary selection of low-producing
MBL haplotypes, particularly in indigenous Africans and South
Americans, is lacking [9,10,59]. We describe for the first time that
MBL enhances EBOV, WNV infections, and to a lesser extent
Hendra and Nipah viruses in low complement conditions. These
findings suggest that certain infectious diseases may have
negatively selected high-producing MBL genotypes and they
provide new insights in EBOV pathogenesis.
According to the currently accepted paradigm, MBL deficiency
predisposes children and immunocompromised individuals to
invasive diseases whereas normal or high levels of MBL are
protective. In contrast to this, we demonstrated here an apparent
paradoxical phenomenon in which recombinant human MBL and
native MBL from a panel of human serum samples enhanced
pseudotyped and wild type-like EBOV infections of human cells
when complement components were reduced or removed
(Figure 1). Heat inactivation of serum had a similar albeit
diminished effect because heat also reduced C4 cleavage activity of
MBL by 39–91% (data not shown).
We demonstrated that MBL binds to EBOV via highly specific
interactions with MBL’s carbohydrate recognition domains, a
process which is calcium-dependent as would be expected for C-
Figure 6. RNA interference screen of candidate cellular receptors for EBOV and MBL. (A–D) We targeted 24 candidate lectin, scavenger
and other putative receptors using pLKO.1 lentiviral vectors that expressed 4 or 5 unique short hairpin RNA (shRNA) constructs per gene. We
transduced HEK293F cells in quadruplicate using 4.66108 viral particles (shRNA-expressing vectors or empty control vectors) with hexadimethrine
bromide (6 mg/ml) at 37uC for 18 hours. We selected transduced cells with 5 mg/ml puromycin over 48 hours and determined cell viability with
alamarBlue reagent (resazurin reduction assay). We then infected cells in quadruplicate with HIV-EBOV GP virion-like particles (1000 pg p24/100 ml)
with or without rhMBL. After 48 hours we measured rates of single-round infection (luciferase assay) and adjusted results for cell viability. Percentage
change in infection was normalized to the empty pLK0.1 control vector (CTRL). Shown are positive hits (A, C) which were defined as $66% reduction
in infection by at least two shRNA constructs for any particular gene. Reductions in protein expression produced by shRNAs (western blots; B, D)
relative to that produced by the empty pLK0.1 control vector are shown. Relative densitometry was performed with ImageJ (NIH) by adjusting for
variations in the actin loading controls (adjusted relative densities for CLEC6A: lane 1, 0.60; lane 2, 0.56; lane 3, 0.51; lane 4, 0.35; control, 1.0. C1QBP:
lane 1, 0.32; lane 2, 0.52; lane 3, 0.47; control 1.0).
doi:10.1371/journal.pone.0060838.g006
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type lectins (Figure S1). We further showed that high affinity MBL
ligands (e.g. D-mannose [6]) competed with viral-binding to MBL
(Figure 2A,B), and 3F8, a neutralizing monoclonal antibody that
binds the hinge region within the MBL carbohydrate recognition
domain [31] blocked enhanced infection (Figure 2C).
We then sought to identify which specific residues on the viral
surface were targeted by MBL. Based on the repertoire of MBL’s
typical ligands, we hypothesized that the targets were glycopro-
teins, which are critical for virus stability, cell tropism, immune
evasion, and host cell invasion. EBOV, and other viruses such as
Hendra and Nipah viruses, WNV, hepatitis C virus, HIV-1, HIV-
2, influenza viruses, metapneumoviruses, and SARS-corona virus
use host cell machinery to modify viral surface proteins by N-
linked glycosylation. This process involves attaching a high-
mannose core to the amide nitrogen of asparagines followed by
trimming and remodeling of viral oligosaccharides in the
endoplasmic reticulum and Golgi apparatus [60]. EBOV GPs
are heavily glycosylated with N- and O-linked glycans that
constitute more than one-third of their molecular mass [61].
The majority of N-linked glycans are concentrated in the GP1
glycan cap and mucin-like region, which are reminiscent of the
glycan shields of HIV gp120 and Epstein-Barr virus gp350. Other
investigators have speculated that glycans may help EBOV evade
immune responses by masking the putative EBOV receptor-
binding region [62,63]. But viral glycans may also be recognized
by C-type lectin receptors that are either membrane-associated
(e.g. DC-SIGN [42]) or soluble (e.g. MBL [6]), and several viruses
can hijack these type of molecules to enter cells and propagate
[60].
We established that MBL binds to N-linked glycans on the viral
surface by showing that cyanovirin-N (a lectin that targets N-linked
high-mannose with great specificity and affinity) competed with
Figure 7. MBL enhances infections by wild type-like EBOV and other glycosylated virions. (A) We preincubated wild type-like EBOV-eGFP
(1976 Mayinga variant) with media alone or 5% MBL-deficient serum with or without rhMBL at 37uC for 1 hour and then infected 46104 HEK293T cells
(multiplicity of infection, 0.1) at 37uC for 1 hour. We measured cellular fluorescence after 72 hours of incubation in fresh media. Comparisons are with
baseline values, * p = 0.028; ** p= 0.037. (B) We preincubated native Hendra and Nipah viruses (10,000 TCID50/ml) with 10% heat-inactivated MBL-
deficient serum with or without rhMBL and then infected Vero E6 cells at 37uC for 1 hour. After 24 hours, infection was detected by
chemiluminescence-based viral protein immunoassays. Comparisons are with baseline values, *p = 0.001; ** p= 0.029. (C) We preincubated 250 ml
West Nile virion-like particle-GFP with media alone or 2% MBL-deficient human serum, with or without rhMBL at 37uC for 1 hour and then transduced
16104 HEK293T cells. Cells were detached using TrypLE and washed three times with PBS at 4uC. Rates of transduction were assayed by flow
cytometry. Comparisons are with baseline values, * p = 0.002; ** p = 0.001. WT refers to wild type; mutant refers to glycosylation mutant of WNV E
protein; hMBL refers to human MBL.
doi:10.1371/journal.pone.0060838.g007
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MBL binding to viruses (Figure 2D) [49]. Furthermore, MBL-
enhanced HIV-EBOV GP infection was significantly diminished
after deglycosylation of virions using PNGase F [50,64] but not
endo H, which leaves an exposed N-acetylglucosamine residue on
the polypeptide chain that may serve as a ligand for MBL
(Figure 3C,D). These findings were confirmed by the fact that
MBL-mediated enhancement of viral infection was abrogated by
thermolysin-treated HIV-EBOV GP virions in a thermolysin-
concentration dependent manner (Figure S4). MBL also had a
significantly reduced capacity to enhance EBOV infection when
the GP lacked a portion of the glycosylated mucin-rich region
(Figure 1B). It is noteworthy, however, that infection levels of
EBOV with mutated GP were higher than those of wild-type GP
pseudotypes, likely because absence of the GP’s mucin-rich region
exposed the putative EBOV receptor binding region which
facilitated infection of cells [33]. On the other hand, MBL did
not enhance infection by VSV-G pseudotyped virions indicating to
some extent MBL’s selectivity.
These findings raised the question whether MBL can cross-link
the virus to putative cell surface receptors. It is known that EBOV
protects itself from host immunity by down-regulating host
proteins including immune regulatory molecules and receptors
such as MHC1 and b1 integrins via steric occlusion, referred to as
the ‘‘glycan umbrella’’ effect [50,65]. To circumvent this
constraint on infection, we propose that EBOV may exploit
putative MBL receptors to enter cells with or without engaging
EBOV-specific receptors. Although the cognate receptor/s for
MBL are not known with certainty, potential receptors for MBL
include CD93 (C1qRp), CD35 (complement receptor 1, CR1),
calreticulin (cC1qR), CD91, and the binding protein for the
globular domain of C1q (gC1qBP/gC1qR/C1QBP) [4,28], all of
which have proven and/or predicted N-linked glycopeptides
[66,67]. Therefore, we tested whether reduction of N-linked
glycoprotein receptor expression [68] by chemical (tunicamycin)
or genetic (HEK293S GnTI2 cells) approaches could reduce
MBL-mediated HIV-EBOV GP infection. Tunicamycin, which
completely inhibits N-linked glycosylation, abrogated MBL-medi-
ated pseudotyped EBOV infection to a greater extent than other
downstream N-glycan-trimming agents such as deoxynojirimycin
and swainsonine which leave residual mannose or GlcNAc
residues (Figure 3E). Similarly, HEK293S N-linked glycosylation-
deficient cells were resistant to MBL-mediated enhancement
(Figure 3F). Taken together, these results showed that MBL
interacts with N-linked glycoproteins trafficked via the ER and
Golgi apparatus. This finding is corroborated by the fact that the
collagenous stalk of MBL binds to calreticulin, a putative receptor
[27] and lung collectins (surfactant proteins A and D) can also bind
ligands via their collagenous tails [69].
The mechanisms of EBOV attachment and internalization have
been studied extensively [17,19,45,47,50,53,70,71,72,73,74,75].
EBOV attaches to various putative attachment factors on the cell
surface [13] where they undergo either clathrin/caveolae/
dynamin-independent, actin/lipid raft-dependent macropinocyto-
sis-like endocytosis [17,70,74] or clathrin/caveolae/dynamin-
dependent endocytosis [75] depending on type of target cells
involved. Virions are then trafficked through early and late
endosomes where they undergo proteolysis in acidified endocytic
vesicles by cathepsin L and/or B which remove the mucin-like
region of GP leading to enhanced viral binding and infectivity
[17,19,33,45,46,47,70]. Previous studies used replication-compe-
tent infectious EBOV, EBOV virion-like particles or pseudotyped
lentiviruses. Findings from our infection assay using EBOV GP
pseudotyped lentiviruses agreed with those of Saeed et al., who
used wild type viruses, to the extent that EBOV undergoes
macropinocytosis-like endocytosis (Figure 4A) in a lipid raft-
dependent (Figure 4B) and dynamin-independent (Figure S5)
manner [17,74]. In addition, we found that MBL diminished the
dependence on actin filaments (but not microtubules) and early
endosomal acidification [70,76] for infection (Figure 4C-F, Figure
S5), suggesting that MBL may traffic viruses via a non-canonical
pathway that resembles the clathrin/caveolin/dynamin/actin-
independent, and microtubule-dependent endocytic pathway
utilized by lymphocytic choriomeningitis virus (LCMV) and
recombinant LCMV-Lassa virus GP infectious virions [77].
Further detailed mechanistic studies are required to confirm these
findings.
To determine if the phenomenon of MBL-dependent enhance-
ment is applicable to clinically relevant targets, we tested a human
monocyte-derived macrophage cell line (Figure 5A) and primary
human macrophages (Figure 5B) which represent the type of cells
targeted early in the course of natural EBOV infection. MBL did
indeed enhance HIV-EBOV GP infection in both types of cells.
We then sought to identify cellular surface receptor(s) that
mediated MBL-enhanced viral infection. We conducted an RNAi
screen using at least 4 unique shRNA-expressing vectors per gene
to mitigate the impact of differential effectiveness and possibility of
off-target effects of shRNAs [40]. We tested our assay by
comparing levels of HIV-EBOV GP infection after knocking
down CTSL1 (Figure S6)[47] and the reduced infectivity was
consistent with the known role of CTSL1 in mediating viral entry.
Using the same techniques, we revealed that knock down of
C1QBP by three shRNA constructs (confirmed by western blot,
Figure 6D) reduced HIV-EBOV GP infection to variable extents
in two of the three shRNA treatments (variability of shRNAs is
well described). Notably, knock down of C1QBP by both shRNAs
was augmented in the presence of MBL but to a significantly
greater extent for the most effective shRNA (65% to 90%
reduction of infection, p,0.005) suggesting that MBL plays a
supplementary role in mediating viral entry (Figure 6C, D).
C1QBP is a tetrameric transmembrane surface protein expressed
on human monocytes and a variety of other cells. It binds the
globular heads of C1q via its amino terminus with high affinity and
contains three potential N-glycosylation sites [78]. C1QBP has
been implicated in innate and adaptive immunity. Viral ligands
have been shown to activate C1QBP translocation which inhibits
RIG-1, an RNA helicase, which in turn inhibits antiviral signaling
by downregulating type I interferons [79]. Given that induction of
RIG-1 inhibits EBOV replication [80] we speculate that EBOV-
MBL complexes activate C1QBP which then negatively regulates
RIG-1 inhibition of viral infection, thereby enhancing viral
proliferation. However, it is not clear how C1QBP avoids binding
to circulating MBL under normal physiological conditions. One
hypothesis is that MBL undergoes a conformational change upon
binding to viral and other targets [81]. This in turn could expose
potential binding sites in MBL’s collagenous stalk for engagement
with C1QBP.
Furthermore, we showed that knock down of the C-type lectin
receptor, dectin-2 reduces experimental infection with EBOV
(Figure 6A). Dectin-2 is expressed on certain macrophages,
monocytes and dendritic cells [82], which are targeted by EBOV
early in the course of infection. This receptor has not been invoked
previously in viral pathogenesis. Further studies will be required to
determine if there are specific physical and/or functional
interactions between EBOV, MBL and dectin-2, and to determine
if this receptor plays a role in native EBOV infections.
Finally, we investigated whether MBL enhances native EBOV
and certain other glycosylated virus infections in low complement
conditions. RhMBL did indeed enhance infection by wild type-like
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EBOV (by 75–150%), West Nile virion-like particles (by 150–
300%), and native Nipah and Hendra viruses (by only 20–35%,
respectively) suggesting that other viruses that are adorned with N-
glycans can also be potentiated by MBL to varying extents
(Figure 7A–C). As expected, MBL-enhancement of EBOV
infection was mitigated by mannan and tunicamycin (Figure S7)
and infection with a WNV glycosylation mutant was not enhanced
by MBL (Figure 7C). It is plausible that life-threatening
glycosylated viruses that form glycosylated virions from the Old
World such as measles and variola viruses exerted pressure on the
evolution of MBL genotypes that was not previously appreciated.
In support of our hypothesis that MBL enhances infections
caused by certain glycosylated virions, there is evidence that
individuals with high MBL concentrations or high-producing
MBL haplotypes experience enhanced infections caused by other
glycosylated intracellular pathogens such as Leishmania spp,
Mycobacterium leprosum and M. tuberculosis, and opportunistic
organisms in HIV-infected individuals [10,83,84,85,86]. Tobin
et al. [87] identified mutations in zebrafish and human leukotriene
A4 hydrolase genes that conferred heterozygous advantage against
Mycobacterium marinum and tuberculosis, respectively. These results set
a groundbreaking precedent in our understanding of how SNPs in
a single human gene can dictate dichotomous inflammatory states:
either inadequate or excessive immune responses can result in
increased severity of TB meningitis in humans. Similarly, we
speculate that under certain circumstances both high and low
levels of MBL may predispose individuals to certain infectious
diseases. Furthermore, our hypothesis that high levels of MBL may
be deleterious is supported conceptually by a recent report that
demonstrated a role for MBL in mediating immune pathology in a
mouse model of Ross River virus (RRV) arthritis; high MBL levels
in serum and synovial fluid of humans with RRV correlated with
disease severity [88]. MBL has also been implicated in murine
models of pandemic H1N1 influenza A and H9N2 avian influenza
A as a risk factor for severe disease by upregulating inflammatory
responses [89]. There is also evidence that inhibition of the lectin
pathway confers considerable protection against non-infectious
disorders such myocardial and gastrointestinal ischemia/reperfu-
sion injury [90]. Therefore, it is possible that evolutionary selection
of mutant MBL alleles conferred protection against a variety of
pathogens and/or reduced the deleterious effects of complement-
mediated inflammation [8,11,83,84,85]. Other examples of
preserved heterozygozity include sickle-cell trait which protects
against malaria despite its disadvantage in healthy populations.
Also, a persistent regulatory mutation in the Duffy antigen
chemokine receptor confers resistance to malaria.
Wide variations in plasma concentrations of MBL and certain
complement components occur naturally. These variations are
due to diversity of genotypes of MBL and complement component
C4, which is encoded by 2 to 8 copies of the C4 gene [91], as well
as other complement components. Partial C4 deficiency is one of
the most common immune protein deficiencies in humans. It is
caused by a complex pattern of differences in gene size, gene
number, and nucleotide polymorphisms. Specifically, homoex-
pression or deletion of C4A or C4B is estimated to occur in 19–
34% of normal Caucasians [92,93]. Total C4A deficiency occurs
in 1% and C4B deficiency in 10% of the Finnish population [94].
The mean C4 protein levels vary between 0.26 and 0.49 g/L in
European Americans and Asian Indian populations [93,95].
However, it is notable that total C4 protein levels span a 1-log
range (approximately 0.1 to 1.0 g/L) with higher concentrations
correlating with a larger number of gene copies [93,95]. Although
the prevalence of homozygous C2 deficiency in Caucasians is rare
(approximately 1/20,000), partial C2 deficiency is estimated to
affect about 1% of western Europeans [96]. In addition, certain
infectious diseases may modulate complement levels e.g. acute
malaria is a pervasive ancient infectious disease that can cause
hypocomplementemia [97,98]. Furthermore, complement may be
reduced to varying extents by certain auto-immune conditions that
drive immune complex formation, although these events are
relatively rare. To investigate our hypothesis that relatively low
levels of complement may permit MBL to enhance viral infection,
we performed infection assays in serially diluted serum. We
observed that serum containing higher concentrations of native
MBL enhanced HIV-EBOV GP infection to the greatest extent
when serum was diluted by at least 10-fold (Figure 1C). We then
showed that the critical factor in serum (diluted only 2-fold) that
abrogated MBL’s capacity to enhance infection is complement
(specifically C2; Figure 1F). It is in this context that we modeled
viral infections using high level rhMBL (10 mg/ml) in 5% serum
(i.e. diluted 20-fold). However, such a high concentration of
rhMBL is considered supraphysiological if adjusted for the 20-fold
dilution factor of serum.
Although human MBL is produced primarily in the liver, extra-
hepatic MBL synthesis has been found in the gastrointestinal tract,
middle ear fluid, and nasopharyngeal secretions. It is possible that
MBL2 expression can be differentially induced in various
compartments in response to different stimuli [99]. Similarly,
extrahepatic complement synthesis and regulation may influence
local concentrations of complement [100]. Furthermore, dysfunc-
tional MASP-2 variants may attenuate its capacity to activate
complement [101]. The frequency of deficient or non-functional
MASP-2 ranges from 2% to 19% in different populations with the
highest values in Africans [102]. We speculate that relative MBL
excess in the setting of relatively low C4 levels or deficient MASP-2 may lead
to MBL-mediated enhanced viral infections in clinical settings.
Thus, we propose that MBL, C4 and MASP-2, among others
contribute to a lattice of immune molecules that represent an
individual’s ‘‘innate immune haplotype’’. Individually, these
effectors may not necessarily dictate the outcome of infections,
but the aggregate immunological state may influence a person’s
susceptibility or resistance to infection.
The precise mechanism by which MBL enhances infections by
glycosylated virions is not known. We speculate that MBL
concentrates virus at the target cell surface under certain
circumstances, such as when MBL exceeds complement levels,
and facilitates cross-linking of EBOV to its cognate receptor or to
other attachment factors such as MGL or dectin-2, which may
facilitate subsequent membrane fusion and internalization or
macropinocytosis (Figure 8).
Our study was potentially limited by the fact that we used
pseudotyped viruses for mechanistic experiments because the
composition of viral envelopes depends in part on the cell type in
which viruses are produced. Therefore, the observed interactions
between HIV-EBOV-GP and host attachment factors may be
artificial. However, we showed a similar phenomenon with wild
type-like EBOV and other glycosylated viruses. Furthermore, it
has been shown that all the GPs of all the Ebolaviruses (EBOV
and relatives) contain high-mannose and hybrid N-linked glycans
independent of the cell line used for viral propagation [64].
Another limitation of our study was the lack of direct evidence
from humans that complement components (specifically C4 or C2)
are sufficiently low in vivo in certain circumstances to permit MBL
to mediate enhanced uptake of glycosylated viruses. We used
media supplemented with 5% human serum which is only half the
concentration of fetal calf or fetal bovine serum typically used for
EBOV infectivity assays [17,18,44,45,67]. Given that C4 gene
copy number variations may lead to a proportionate reduction of
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circulating C4 [88], we speculate that the experimental ratios of
MBL:C4 used in this study are physiologically plausible. A recent
clinical study by Kainulainen et al. [94] provided preliminary data
which are consistent with our hypothesis that synergy between C4
deficiency and MBL excess may predispose children and
adolescents to certain infections: 26% (n= 22) of Finnish patients
with recurrent respiratory infections vs.14% (n= 10) of healthy
controls (p = 0.048) had C4A deficiency. Not unexpectedly, 50%
of the patients with C4A deficiency had MBL concentrations
.1.5 mg/ml, the mean human MBL serum concentration but
notably, more than one-third had very high MBL levels (.4 mg/
ml). Further clinical studies are required to investigate the
significance of this apparent association.
In conclusion, this study reveals MBL’s complex role in
infections caused by EBOV and other glycosylated viruses.
MBL, which is a key innate immune molecule, seemingly has
paradoxical functions depending on the levels of complement
[6,15]. We demonstrate for the first time the phenomenon of
MBL-dependent enhancement of infections caused by glycosylated
virions in low complement conditions and discover roles for
C1QBP and dectin-2 in EBOV pathogenesis. We postulate that an
individual’s innate immune haplotype is defined by the interac-
tions between the genotypes of MBL, C4 and possibly others. Our
findings highlight the possibility that administration of supraphys-
iological doses of MBL products or blood products with high MBL
concentrations to individuals in the setting of infectious diseases
and relative hypocomplementemia may be deleterious under
certain conditions. On the other hand, it is intriguing to consider
that MBL might be used as an adjuvant to enhance delivery of
glycosylated vaccine epitopes to effectors of the immune system.
Finally, these findings suggest that the pressure of infectious
diseases may have driven, in part, the evolutionary selection of
MBL mutant haplotypes that encode low or intermediate MBL
serum levels in the majority of humans.
Supporting Information
Figure S1 RhMBL enhances HIV-EBOV GP infection in
a calcium-dependent manner. We preincubated HIV-
EBOV-GP virion-like particles with rhMBL in 5% MBL-deficient
serum and Veronal-buffered saline with or without calcium
supplementation. *, ** and { p,0.05 (5 mM CaCl2 versus 0 or
2 mM CaCl2 at 0, 0.1 and 1 mg/ml rhMBL, respectively); {
p,0.001 (all pairwise comparison at 10 mg/ml rhMBL). Exper-
iments were performed twice in quadruplicate.
(EPS)
Figure S2 MBL activity in sera from a panel of healthy
subjects. We measured native MBL concentrations (mannan-
binding activity) and MBL C4 cleavage activity in sera from 35
healthy adult volunteers of Caucasian, Asian, Hispanic or African-
American ancestry (females, n = 20). The sample had a 3.7 log10
range of MBL concentrations (0–5,424 ng/mL) that were strongly
correlated with the concordant MBL C4 cleavage values (0–
7,468 U/mL; r2 = 0.91). The sample included three individuals
with homozygous MBL2 null alleles (B, C, D) who had no
detectable MBL (lower limits of detection: MBL concentration,
0.6 ng/ml; C4 cleavage activity, 1.6 U/ml). As expected,
significantly more individuals with wild-type MBL2 haplotypes
(A/A) had MBL concentration .500 ng/ml (12/21 vs 2/14,
p,0.03) and MBL C4 cleavage activity.500 U/mL (13/21 vs 1/
14, p,0.005) compared with MBL2 O/O or O/A haplotypes (O
refers to B,C or D alleles).
(EPS)
Figure S3 Endoglycosidases cleave N-linked glycans in
HIV-EBOV GP. We preincubated HIV-EBOZ GP virion-like
particles (12,000 pg/ml) with PNGase F or endo H (10,000 U/ml
each) diluted in DMEM or with DMEM alone for 1 hour at 37uC.
Viruses then underwent gel electrophoresis; products were
transferred onto a nitrocellulose membrane and were detected
by further incubation with biotinylated Hippeastrum Hybrid Lectin
(1:500) followed by streptavidin-horseradish peroxidase (HRP;
1:5000). Membranes were then incubated with Immobilon
Western Chemiluminescent AP substrate and exposed to autora-
diography film. High-mannose moieties were preserved only in
untreated virus confirming that PNGase F and endo H effectively
cleaved high-mannose residues on GPs of HIV-EBOV virion-like
particles.
(EPS)
Figure S4 Thermolysin treatment of HIV-EBOV GP
abrogates enhancement of infection by rhMBL in a
thermolysin-concentration dependent manner. We prein-
cubated HIV-EBOV GP virion-like particles (1200 pg p24/
100 mL) without or with thermolysin (31.3, 62.5, 125, 250 mg/
ml) in buffer (40 mM HEPES, 40 mM MES, 50 mM NaCl,
0.1 mM CaCl2) shaking for 30 minutes at 37uC. The reactions
were then terminated with 0.1 mM EDTA. HEK293F cells were
infected with thermolysin-treated virion-like particles mixed with
Figure 8. Proposed model of MBL-mediated macropinocytosis
of EBOV. MBL carbohydrate recognition domains (CRD) bind to highly
glycosylated mucin-rich regions of EBOV GP and the MBL-virion
complex is presented to the cell surface. Then MBL binds to cognate
cellular receptors, such as C1QBP or calreticulin [6] via MBL collagenous
stalks. In this manner, MBL concentrates virus at the cell surface and
may facilitate cross-linking of EBOV to its cognate receptor or to other
attachment factors such as dectin-2, which may facilitate subsequent
membrane fusion and internalization. The relatively large size of EBOV
particles (800 to 1,400 nm) is amenable to bulk fluid-phase uptake
pathways such as macropinocytosis which is the canonical pathway for
EBOV entry. Our data indicate that MBL also mediates internalization of
virus via macropinocytosis but suggests that MBL-mediated uptake
preferentially utilizes microtubules compared with the canonical EBOV
pathway which is dependent on both microtubules and actin.
doi:10.1371/journal.pone.0060838.g008
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MBL-deficient (,0.6 ng/ml) 5% human serum alone or with the
same supplemented with 10 mg/ml rhMBL as described in
Materials and Methods. Luciferase values were adjusted for cell
viability using alamarBlue (resazurin reduction assay). Shown are
average adjusted luciferase results from two experiments each with
four replicates. The maximal reduction of viral infection was 17-
fold in the presence of rhMBL, whereas there was no inhibition of
infection in the absence of MBL.
(EPS)
Figure S5 MBL-mediated macropinocytosis of HIV-
EBOV GP may bypass early endosomes and is dynamin
independent. We preincubated HEK293F cells with (A)
amiloride hydrochloride, an inhibitor of Na+/H+ exchanger
activity, (B) bafilomycin A1, a specific and potent inhibitor of
vacuolar H+ ATPase in early endosomes, (C) monensin, an
inhibitor of both endosomal acidification and receptor recycling,
and (D) dynasore, a potent and specific dynamin inhibitor (which
is involved in clathrin- and caveolin-mediated endocytosis) in 5%
MBL-deficient serum in the absence or presence of rhMBL at
37uC for 1 hour. We then infected cells with HIV-EBOV-GP
virion-like particles (1200 pg p24/100 ml). Percentages of infected
cells are relative to DMSO controls (a methanol control was used
for monensin). Luciferase values were adjusted for cell viability
using alamarBlue (resazurin reduction assay). Significant differ-
ences are shown. Experiments were performed twice in quadru-
plicate.
(EPS)
Figure S6 shRNA knockdown of cathepsin-L (CTSL1)
and MGL (CLEC10A).We performed RNA interference with a
pLK0.1 vector encoding shRNAs that targeted (A) CTSL1 and (B)
MGL (CLEC10A) as described for Figure 6. Luciferase values
were adjusted for cell viability. Percentage change in infection was
normalized to an empty pLK0.1 control vector.
(EPS)
Figure S7 rhMBL targets N-linked glycans on surfaces
of wild type-like EBOV and HEK293T cells. (A) We
preincubated 5% MBL-deficient serum (with or without MBL
supplementation) with media or mannan (1 mg/ml) at 37uC for
1 hour. Then we incubated wild type-like EBOV-eGFP (1976
Mayinga variant) with the above preparations at 37uC for 1 hour.
Finally, we infected 46104 HEK293T cells with virions at a
multiplicity of infection of 0.1. (B) We preincubated (i) HEK293T
cells with varying concentrations of tunicamycin and (ii) wild type-
like EBOV-eGFP with 5% MBL-deficient serum (with or without
rhMBL supplementation) at 37uC for 1 hour. Then we infected
46104 HEK293T cells with virus at a multiplicity of infection of
0.1. Fluorescence was assayed 72 hours after infection. Significant
differences are shown. Experiments were performed in triplicate.
(EPS)
Table S1 List of human genes included in RNA inter-
ference (RNAi) screen.
(DOC)
Table S2 Primers for qRT-PCR assays.
(DOC)
Methods S1 Supplementary methods.
(DOC)
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